108 related articles for article (PubMed ID: 38602733)
1. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.
de Lima JD; de Paula AGP; Yuasa BS; de Souza Smanioto CC; da Cruz Silva MC; Dos Santos PI; Prado KB; Winter Boldt AB; Braga TT
Immunol Invest; 2023 Apr; 52(3):364-397. PubMed ID: 36745138
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy activates inflammasomes to cause inflammation-associated bone loss.
Wang C; Kaur K; Xu C; Abu-Amer Y; Mbalaviele G
Elife; 2024 Apr; 13():. PubMed ID: 38602733
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic NLRP3 and AIM2 Inflammasomes Promote Diabetes-Accelerated Atherosclerosis, but Increased Necrosis Is Independent of Pyroptosis.
Hsu CC; Fidler TP; Kanter JE; Kothari V; Kramer F; Tang J; Tall AR; Bornfeldt KE
Diabetes; 2023 Jul; 72(7):999-1011. PubMed ID: 37083999
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Secretion and Pyroptosis of Thyroid Follicular Cells Mediated by Enhanced NLRP3, NLRP1, NLRC4, and AIM2 Inflammasomes Are Associated With Autoimmune Thyroiditis.
Guo Q; Wu Y; Hou Y; Liu Y; Liu T; Zhang H; Fan C; Guan H; Li Y; Shan Z; Teng W
Front Immunol; 2018; 9():1197. PubMed ID: 29915579
[TBL] [Abstract][Full Text] [Related]
5. Enterococcus Faecalis activates NLRP3 inflammasomes leading to increased interleukin-1 beta secretion and pyroptosis of THP-1 macrophages.
Ran S; Huang J; Liu B; Gu S; Jiang W; Liang J
Microb Pathog; 2021 May; 154():104761. PubMed ID: 33524566
[TBL] [Abstract][Full Text] [Related]
6. Exogenous nanoparticles and endogenous crystalline molecules as danger signals for the NLRP3 inflammasomes.
Shirasuna K; Karasawa T; Takahashi M
J Cell Physiol; 2019 May; 234(5):5436-5450. PubMed ID: 30370619
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils Facilitate Prolonged Inflammasome Response in the DAMP-Rich Inflammatory Milieu.
Son S; Yoon SH; Chae BJ; Hwang I; Shim DW; Choe YH; Hyun YM; Yu JW
Front Immunol; 2021; 12():746032. PubMed ID: 34659244
[TBL] [Abstract][Full Text] [Related]
8. M2b macrophages protect against doxorubicin induced cardiotoxicity via alternating autophagy in cardiomyocytes.
Chen S; Huang Y; Huang S; Zhou Z; Liu K; Pan J; Wu Z
PLoS One; 2023; 18(7):e0288422. PubMed ID: 37498828
[TBL] [Abstract][Full Text] [Related]
9. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors.
Jang JY; Kim D; Kim ND
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176164
[TBL] [Abstract][Full Text] [Related]
10. Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.
Eljack S; Allard-Vannier E; Misericordia Y; Hervé-Aubert K; Aubrey N; Chourpa I; Faggad A; David S
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432729
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis.
Abe K; Ikeda M; Ide T; Tadokoro T; Miyamoto HD; Furusawa S; Tsutsui Y; Miyake R; Ishimaru K; Watanabe M; Matsushima S; Koumura T; Yamada KI; Imai H; Tsutsui H
Sci Signal; 2022 Nov; 15(758):eabn8017. PubMed ID: 36318618
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin Induces Bone Loss by Increasing Autophagy through a Mitochondrial ROS/TRPML1/TFEB Axis in Osteoclasts.
Park HJ; Yoon SY; Park JN; Suh JH; Choi HS
Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 36009195
[TBL] [Abstract][Full Text] [Related]
13. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling.
Xian H; Watari K; Sanchez-Lopez E; Offenberger J; Onyuru J; Sampath H; Ying W; Hoffman HM; Shadel GS; Karin M
Immunity; 2022 Aug; 55(8):1370-1385.e8. PubMed ID: 35835107
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.
Blayney DW; Schwartzberg L
Cancer Treat Rev; 2022 Sep; 109():102427. PubMed ID: 35785754
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
